In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Immunicon cuts staff 40%

This article was originally published in The Gray Sheet

Executive Summary

Cell and molecular-based human diagnostic and life sciences research firm reduces its workforce by 45 employees, or 40% of its full-time equivalent platform development, R&D and marketing staff. The reduction in force comes after the firm recently lost its bid to end a 20-year exclusive marketing agreement with Johnson & Johnson/Veridex for its CellSearch cancer test, and reflects the potential impact of the arbitration decision on Immunicon's commercialization efforts, the firm says (1"The Gray Sheet" March 10, 2008, In Brief). The company expects to take a related charge of $1.3 million-$1.5 million in the first fiscal quarter of 2008

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts